Next Article in Journal
Matrix metalloproteinase-3 gene polymorphism and dilatative pathology of ascending thoracic aorta
Previous Article in Journal
The evaluation of psychomotor development in preterm infants
 
 
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug

by
David Vetchy
1,*,
Martina Vetcha
2,
Miloslava Rabiškova
1,
Eva Gryczova
1 and
Lenka Bartošikova
2
1
Department of Pharmaceutics
2
Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Brno University of Veterinary and Pharmaceutical Sciences, Czech Republic
*
Author to whom correspondence should be addressed.
Medicina 2007, 43(4), 326; https://doi.org/10.3390/medicina43040040
Submission received: 11 April 2006 / Accepted: 30 March 2007 / Published: 4 April 2007

Abstract

After patent protection of original brand is over, there are a lot of generic products occurring on the pharmaceutical market. It may be the way to reduce the price, but on the other hand, one should expect the same quality and almost identity with original brand, because the development of generic drugs is based on pharmacological properties of the original brand. The aim of this study was to compare the similarity of two products with controlled release of felodipine – generic product Presid® and original brand Plendil® – which are commercially available in Czech Republic, based on in vitro dissolution testing. The dissolution test in three dissolution media of increasing pH (1.2, 4.5, and 6.5) for the simulation of physiological pH within the gastrointestinal tract confirmed controlled release of felodipine from the original product Plendil ER 5 mg and Plendil ER 10 mg during the period of 24 hours. The release of felodipine from generic products Presid 5 mg and Presid 10 mg was not controlled for 24 hours as it is indicated in the information leaflet. In the generic products, felodipine release was controlled just for 12 or 18 hours and in this respect did not show similarity with the original brand. Since patients take the drug just once a day in the morning, the controlled release of felodipine, which lasts only 12 to 18 hours, can cause insufficient blood pressure control especially in the most critical morning hours and higher cardiovascular risk.
Keywords: felodipine; dissolution study; controlled release; comparison felodipine; dissolution study; controlled release; comparison

Share and Cite

MDPI and ACS Style

Vetchy, D.; Vetcha, M.; Rabiškova, M.; Gryczova, E.; Bartošikova, L. Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Medicina 2007, 43, 326. https://doi.org/10.3390/medicina43040040

AMA Style

Vetchy D, Vetcha M, Rabiškova M, Gryczova E, Bartošikova L. Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Medicina. 2007; 43(4):326. https://doi.org/10.3390/medicina43040040

Chicago/Turabian Style

Vetchy, David, Martina Vetcha, Miloslava Rabiškova, Eva Gryczova, and Lenka Bartošikova. 2007. "Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug" Medicina 43, no. 4: 326. https://doi.org/10.3390/medicina43040040

Article Metrics

Back to TopTop